Abstract
CXCR3 and CCR5 are chemokine receptor that are predominantly expressed on the surface of Th1 polarized T cells. In a variety of human and experimental autoimmune diseases the enhanced expression of CXCR3 and CCR5 binding chemokine ligands is followed by the recruitment of CXCR3- and CCR5-positive T cells, indicating an important role for these chemokine receptors in T cell-mediated tissue damage. In this review, we summarize a number of in vivo studies available on the neutralization of CXCR3 and CCR5 in inflammatory disease, and specifically focus on the potential therapeutic effects of CXCR3 and CCR5 blockade in human autoimmune disease and organ transplantation.
Keywords: Chemokine receptor, T cell, autoimmune disease, transplantation, inflammation
Mini-Reviews in Medicinal Chemistry
Title: Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Volume: 7 Issue: 11
Author(s): J. E. Turner, O. M. Steinmetz, R. A. Stahl and U. Panzer
Affiliation:
Keywords: Chemokine receptor, T cell, autoimmune disease, transplantation, inflammation
Abstract: CXCR3 and CCR5 are chemokine receptor that are predominantly expressed on the surface of Th1 polarized T cells. In a variety of human and experimental autoimmune diseases the enhanced expression of CXCR3 and CCR5 binding chemokine ligands is followed by the recruitment of CXCR3- and CCR5-positive T cells, indicating an important role for these chemokine receptors in T cell-mediated tissue damage. In this review, we summarize a number of in vivo studies available on the neutralization of CXCR3 and CCR5 in inflammatory disease, and specifically focus on the potential therapeutic effects of CXCR3 and CCR5 blockade in human autoimmune disease and organ transplantation.
Export Options
About this article
Cite this article as:
Turner E. J., Steinmetz M. O., Stahl A. R. and Panzer U., Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases, Mini-Reviews in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/138955707782331768
DOI https://dx.doi.org/10.2174/138955707782331768 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Neurological Involvement as the Initial Manifestation in Primary Sjögren's Syndrome - A Case Report
Current Rheumatology Reviews Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design Roles of Glycans and Glycopeptides in Immune System and Immune-Related Diseases
Current Medicinal Chemistry